Leggett & Platt Announces 4Q and Full Year 2025 Earnings Call Carthage, MO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Leggett & Platt (NYSE:LEG), a diversified manufacturer of engineered products serving several major markets, will release fourth quarter and full year earnings results on Wednesday, February 11, 2026 after the market closes, and hold its quarterly conference call to discuss fourth quarter and full year results, annual guidance, market conditions, company initiatives, and related matters on Thursday, February 12, 2026, at 8:30 a.m. Eastern Time (7:30 a.m. Central Time). This call...
Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue PONTE VEDRA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced its preliminary, unaudited fourth quarter and full-year 2025 revenue results. Highlights: Preliminary revenue of $62.1 million to $62.5 million in the fourth quarter of 2025, an approximate 9% decrease at the midpoint over the same period ...
Treace Announces First Surgical Case Utilizing Lapiplasty® Lightning™ Technology PONTE VEDRA, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced the successful completion of the first case utilizing its Lapiplasty® Lightning™ technology. Lightning technology expands upon Treace’s market-leading Lapiplasty® System with advanced new instrumentation designed to reduce surgical steps, pr...
Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications - Data is from comprehensive review of hospital charges and all-payer claims over five years - - Preventable complications such as amputation and conduit infection increased initial hospital charges by approximately $493,000 and $590,000 per patient respectively – - Humacyte’s Symvess® has consistently demonstrated low rates of infection and high rates of limb salvage – DURHAM, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage bio...
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel - Expansion plans are based on requests for product access received from surgeons and hospitals in Israel - - Expansion of Symvess into other territories, including those in Europe and the Middle East, is also planned - DURHAM, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it plans to file a Marketing Authorization Applica...
Treace to Present at 44th Annual J.P. Morgan Healthcare Conference PONTE VEDRA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that John T. Treace, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, beginning at approximately 7:30 am PT. A live webcast and replay of the fireside chat will be available on the ...
Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair - Results published in Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) - - After up to 36 months of follow-up, patients demonstrated high limb salvage, low rates of infection, no unprovoked structural failures - - Results represent first prospective long-term data in traumatic arterial repair using an off-the-shelf biologic conduit - DURHAM, N.C., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platfor...
Treace Medical Secures Up to $175 Million in Debt Financing New 5-Year Agreement Provides Continued Financial Strength & Flexibility PONTE VEDRA, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it has entered into a new five year $175 million senior secured loan arrangement with credit funds managed by SLR Capital Partners, consisting of $60 million in term loans funded at close,...
Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital DURHAM, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has entered into a credit facility with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group, providing up to $77.5 million in principal amount of new financing. The credit agreement, which has a term of four years, includes an initial tranche of $40 millio...
Norwegian Cruise Line Holdings Appoints Marc Kazlauskas as President of Norwegian Cruise Line Kazlauskas brings decades of experience leading global travel companies and delivering guest-centric innovation MIAMI, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) today named travel industry veteran Marc Kazlauskas as President of Norwegian Cruise Line (Norwegian), effective Jan. 19, 2026. He joins the company with more than 30 years of senior leadership experience across sales, operations, and innovation in the global travel industry. Kazlauskas most rec...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Nuveen New Jersey Quality Muni Income Fd and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 18 November 2025 in which we reassessed the appropriateness of the...
Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results – Post-implantation analysis of ATEVs demonstrates progressive recellularization with host cells, transforming the ATEV into a multi-layered living tissue similar to that of native blood vessels – – Positive outcomes for dialysis patients suffering from Steal syndrome who were treated with the ATEV – – Additional presentations report durable two-year outcomes for patients treated in Ukraine conflict, superior two-year outcomes for female dialysis patient...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.